Gensight Biologics Cash Runway Confirmed To June 2023

March 24 (Reuters) - Gensight Biologics SA:

* CASH RUNWAY CONFIRMED TO JUNE 2023

* EFFORTS TO REDUCE CASH BURN IN 2023 WHILE SECURING LUMEVOQ MANUFACTURING AND PREPARING FOR COMMERCIAL LAUNCH IN EUROPE IN H1 2024

* ADVANCED DISCUSSIONS ON REFINANCING BRIDGE WITH CERTAIN SHAREHOLDERS ONGOING, TARGETED CLOSING IN COMING WEEKS

* OPERATING INCOME REDUCED BY 36.9% TO EUR 4.9 MILLION IN 2022 FROM EUR 7.7 MILLION IN 2021

* CASH AND CASH EQUIVALENTS TOTALED EUR 10.6 MILLION AS OF DECEMBER 31, 2022

* COMPANY'S OPERATING LOSS WAS STABLE IN 2022 AMOUNTING TO EUR 27.8 MILLION COMPARED TO EUR 28.1 MILLION IN 2021

* FINANCIAL PROFIT IN 2022 AMOUNTED TO EUR 0.2 MILLION COMPARED TO A LOSS OF EUR (0.5) MILLION IN 2021

* COMPANY'S NET LOSS IN 2022 AMOUNTED TO EUR 27.6 MILLION COMPARED TO EUR 28.6 MILLION IN 2021

* COMPANY HAS TAKEN MEASURES AIMED AT REDUCING ITS OPERATING CASH BURN IN 2023 Source text for Eikon: Further company coverage: (Gdansk Newsroom)